Skip to main content Skip to main navigation menu Skip to site footer


Ocular surface squamous neoplasia is a spectrum of lesion which ranging from conjunctiva-corneal intraepithelial dysplasia (CIN), carcinoma in situ to invasive squamous cell carcinoma (SCC). Management of choice for OSSN is total excision with no-touch technique.Additional therapy is needed to prevent recurrency.The additional therapyare topical chemotherapy agent such as mytomicin-C (MMC), 5-fluorouracil (5-FU) or cryotherapy. Aim of this study is to understand the characteristic, complication and recurrency of OSSN therapy in Sanglah hospital.This study was an observational retrospective cross sectional study. Data were collected from the medical records from 2013 to 2015. Subjects were 10 patients and mostly were men. Mean age of the samples was 42.80 (SD 21.617) years old, ranging between eight to 70 years old. Proportion between right and left eye was equal. Tumor were found mostly in nasal area.Farmer was the most common job in samples with the last education was elementary school. Scleromalacia complication was found only in one patient who had been given MMC for the additional therapy. In two samples who only had primary excision, we found one patient with a reccurent tumor. All samples who got MMC for the additional therapy had a recurrency. All samples who got cryotherapy for the additional therapy had no recurrency. Excisional biopsy with cryotherapy less likely to recurrent with minimal risk of complication.





  1. Barros JN, Lowen MS, Moraes-Filho MN, Martins MC. Use of impression cytology for the detection of unsuspected ocular surface squamous neoplasia cells in pterygia. Arq Bras Oftalmol.2014;77(5):305-9
  2. American Academy of Ophthalmology Staff. Ophthalmic Pathology and Intraocular Tumors. BCSC Section 4. San Fransisco; 2014.h.61-75
  3. Tananuvat N, Lertprasertsuke N. Ocular Surface Squamous Neoplasia, Intraepithelial Neoplasia.Penyunting, Dr. Supriya Srivastava. ISBN: 978-953-307-987-5, InTech. 2012. Diunduh dari: (Diakses 25 February 2016).
  4. Radhakrishnan, A. Ocular Surface Squamous Neoplasia (OSSN) – A Brief Review, Kerala Journal of Ophthalmology. 2011;23(4):347-51.
  5. Nanji AA, Moon CS, Galor A, SeinJ, Oellers P, Karp CL. Surgical versus medical treatment of ocular surface squamous neoplasia: A comparison of recurrences and complications. Ophthalmology. 2014;1:1-7.
  6. Mittal R, Rath S, Vemuganti. GK. Ocular surface squamous neoplasia – Review of etio-pathogenesis and an update on clinico-pathological diagnosis. Saudi Journal ofOphthalmology. 2013; 27:177–86.
  7. McClellan AJ, McClellan AL, Pezon CF, Karp CL, Feuer W, Galor A. Epidemiology of ocular surface squamous neoplasia in a veterans affairs population. Cornea. 2013; 32(10):1354-8.
  8. Pfeifer GP, You YH, Besaratinia A. Mutations induced by ultraviolet light. Mutat. Res. 2005; 571:19–31
  9. Ikehata H, Ono T. The mechanisms of UV mutagenesis. J. Radiat. Res.2011; 52:115–25
  10. Xu Z, Taylor JA. Genome-wide age-related DNA methylation changes in blood and other tissues relate to histone modification, expression, and cancer. Carcinogenesis. 2014;35(2):356–64
  11. Waddell M, Downing R, Lucas S, Newton R. Corneo-conjunctival carcinoma in Uganda. Eye (Lond.). 2006;20:893–9
  12. Sudhalkar A. Fixation and its role in the causation, laterality and location of pterygium: a study in amblyopes and non-amblyopes. Eye(Lond.). 2012;26:438–43
  13. Chowdhury RK, Dora J. Clinical Profile of Ocular Surface Squamous Neoplasia A Retrospective Case series. IOSR Journal of Dental and Medical Sciences (IOSR-JDMS). 2014;13(9):53-5
  14. Gupta S, Sinha R, Sharma N, Titiyal J. Ocular Surface Squamous Neoplasia. Del J Ophthalmol. 2013;23(2):89-96
  15. Chen C, Louis D, Dodd T, Muecke J. Mitomycin C as an adjunct in the treatment of localised ocular surface squamous neoplasia. Br J Ophthalmol. 2004;88:17–8
  16. Shin HY, Kim MS, Chung SK. The Development of Scleromalacia after Regional Conjunctivectomy with the Postoperative Application of Mitomycin C as an Adjuvant Therapy. Korean J Ophthalmol. 2013;27(3):208-10
  17. Finger PT, Yousef YA. Conjunctival Tumors. Ophthalmology. 2012;119:233-40
  18. Parrozzani R, Lazzarini D, Alemany-Rubio E, Urban F, Midena E. Topical 1% 5-Fluoruracil in Ocular Surface Squamous Neoplasia: a Long-term Safety Study. International Congress of Ocular Oncology. 2009;1-5
  19. Rahimi F, Alipour F, Hashemi H, Hashemian MN. Topical Mitomycin C for Partially Excised Ocular Surface Squamous Neoplasia. Iranian Journal of Ophthalmology. 2006;19(2):27-30
  20. Rudkin AK, Dempster L, Muecke JS. Management of diffuse ocular surface squamous neoplasia: efï¬cacy and complications of topical chemotherapy. Clinical and Experimental Ophthalmology. 2015;43:20–5
  21. Ghanavati SZ, Alizadeh R, Sophie D. Topical Interferon Alpha‑2b for Treatment of Noninvasive Ocular Surface Squamous Neoplasia with 360° Limbal Involvement. Journal of Ophthalmic and Vision Research. 2014;9(4):423-6

How to Cite

Ardjaja, Y. K. (2017). Karakteristik penderita ocular surface squamous neoplasia di RSUP Sanglah Denpasar tahun 2013-2015. Medicina, 48(3).




Search Panel

Yenita Khatania Ardjaja
Google Scholar
Medicina Journal